Core Viewpoint - BigBear.ai Holdings, Inc. is under investigation for potential securities fraud and unlawful business practices following the disclosure of restated financial statements [1][2] Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors of BigBear.ai Holdings, Inc. regarding possible securities fraud or other unlawful business practices [1] - The investigation is focused on whether BigBear and certain officers and/or directors have engaged in misconduct [1] Group 2: Financial Disclosure - On March 18, 2025, BigBear disclosed that certain financial statements since fiscal year 2021 should no longer be relied upon and would be restated due to accounting treatment issues related to convertible notes due in 2026 [2] - Following this announcement, BigBear's stock price fell by $0.52 per share, or 14.9%, closing at $2.97 per share on the same day [2]

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fid ...

NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Teleflex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. Attorney advertising. Prior results do not guarantee similar outcomes. C ...

NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RLX Technology Inc. ("RLX" or the "Company") (NYSE: RLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether RLX and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On this news, RLX's Amer ...

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fid ...

NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BigBear.ai Holdings, Inc. ("BigBear" or the "Company") (NYSE: BBAI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether BigBear and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On this n ...

Core Insights - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving KinderCare Learning Companies, Inc. and its officers or directors [1] - KinderCare conducted its IPO on October 9, 2024, selling 24 million shares at $24.00 each [3] - The company reported an operational loss of $89.3 million for Q4 2024, a significant decline from an operational income of $48.7 million in the previous year, attributed to increased equity-based compensation and lower COVID-19 stimulus reimbursements [4] - Following the financial results announcement, KinderCare's stock price dropped by $3.92, or 22.17%, closing at $13.76 on March 21, 2025 [5] Company Financials - KinderCare reported an operational loss of $89.3 million for Q4 2024, compared to an operational income of $48.7 million in Q4 2023 [4] - The company provided full-year guidance for 2025 that did not meet consensus estimates [4] Stock Performance - KinderCare's stock price fell by 22.17% to $13.76 per share following the announcement of its financial results [5]

NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, an ...

Core Viewpoint - A class action lawsuit has been filed against Merck & Co., Inc. concerning allegations of securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that Merck and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Merck securities during the Class Period have until April 14, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Financial Impact - On July 30, 2024, Merck reported a significant reduction in demand for its HPV vaccination Gardasil in China, leading to higher inventory levels and potential shipment shortfalls [4]. - Following this announcement, Merck's stock price dropped by $12.53 per share, or 9.81%, closing at $115.25 per share [5]. - On February 4, 2025, Merck announced it would not meet the previously forecasted $11 billion sales target for Gardasil by 2030, leading to another stock price decline of $9.05 per share, or 9.07%, closing at $90.74 per share [5].

Core Viewpoint - A class action lawsuit has been filed against Geron Corporation and certain officers for alleged violations of federal securities laws during the Class Period from February 28, 2024, to February 25, 2025, seeking damages for investors who acquired Geron securities during this time [1]. Company Overview - Geron Corporation is a late-stage clinical biopharmaceutical company focused on developing therapeutics for cancer and chronic degenerative diseases, with its sole product candidate being RYTELO (imetelstat), a telomerase inhibitor aimed at treating low- to intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis [4]. - RYTELO was commercially launched in June 2024 after receiving FDA approval for treating adult patients with lower-risk MDS who are transfusion-dependent and have not responded to or are ineligible for erythropoiesis-stimulating agents [5]. Allegations and Financial Performance - The lawsuit alleges that throughout the Class Period, Geron made materially false and misleading statements regarding its business and prospects, including the potential profitability of RYTELO and the company's ability to meet the unmet needs in the market [6]. - On February 26, 2025, Geron reported Q4 2024 earnings per share of -$0.04 and revenue of $47.54 million, significantly below analyst projections of -$0.02 to -$0.03 EPS and $61.93 million in revenue [7]. - Following the disappointing financial results, Geron's CEO indicated that the company had observed flat revenue trends for RYTELO, attributing this to seasonality, competition, and a lack of awareness among healthcare providers [8]. Market Reaction - After the announcement of the Q4 results, Geron's stock price fell by $0.76 per share, or 32.06%, closing at $1.61 per share on February 26, 2025 [9].